Erasca(ERAS)
SAN DIEGO, CA
BiotechnologyFocus: Cancer Therapies
Erasca is a life sciences company focused on Cancer Therapies.
Oncology
Funding Stage
PUBLIC
Open Jobs
2
Pipeline & Clinical Trials
ERAS-0015
Metastatic Solid TumorsClinical Trials (1)
NCT06983743A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Phase 1ERAS-4001
Metastatic Solid TumorsClinical Trials (1)
NCT07021898A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
Phase 1ERAS-801
Glioblastoma MultiformeClinical Trials (1)
NCT05222802A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)
Phase 1Naporafenib
Advanced or Metastatic Solid TumorsClinical Trials (1)
NCT05907304A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
Phase 1Phase 1
Clinical Trials (1)
NCT04670679A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT04959981A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC
Phase 1Phase 1/2
Clinical Trials (1)
NCT04866134A Study of ERAS-007 as Monotherapy or in Combination With ERAS-601 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2ERAS-007
Acute Myeloid LeukemiaClinical Trials (1)
NCT05279859A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Hematologic Malignancies
Phase 1/2ERAS-007
Metastatic Colorectal CancerClinical Trials (1)
NCT05039177A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies
Phase 1/2Naporafenib
Advanced or Metastatic NRAS-mutant MelanomaClinical Trials (1)
NCT06346067A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Phase 3Open Jobs (2)
Interview Prep Quick Facts
Portfolio: 10 clinical trials
SEC Filings: 2 available
Open Roles: 2 active jobs
Hiring Trend
Stable
2
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles